Stanford University and Starkey Collaborate on Groundbreaking Study Validating Balance Assessment for Fall Risk Detection
EDEN PRAIRIE, Minn., Feb. 13, 2025 /PRNewswire/ -- Starkey continues to be at the forefront of technology and innovation and...
Neurology
Remote Patient Monitoring Market to Hit USD 56.94 Billion by 2030 with 12.7% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global remote patient monitoring market, valued at US$24.39 billion in 2023,...
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany
Ad hoc announcement pursuant to Art. 53 LR AGAMREE® is the first product to receive an agreed federal price in...
Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD
First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food...
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension Saqib Islam, SpringWorks Therapeutics...
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension Saqib Islam, SpringWorks Therapeutics...
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat PlatformSARASOTA, Fla....
GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic’s Specialty Diagnostic SuiteGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx...
GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic’s Specialty Diagnostic SuiteGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx...
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in...
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application...
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial...
Ashvattha to Present at Upcoming Angiogenesis, Exudation, and Degeneration 2025 and BIO CEO Conferences
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of...
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for...
Celebrating the Winners of the Inaugural Sony Women in Technology Award with Nature
NEW YORK and LONDON and BERLIN and TOKYO, Feb. 4, 2025 /PRNewswire/ -- Sony Group Corporation (Sony) and Nature are proud...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced...
Blue Cross Blue Shield of Massachusetts Publishes Positive Reimbursement Policy for the Nerivio® REN Wearable for Acute and Preventive Treatment of Migraine
Nearly three million members of the largest health insurance plan in Massachusetts are now eligible for reimbursement when prescribed with...
MintNeuro Wins Three UK Government ARIA Awards to Apply Advanced Chip Technology to Neural Devices
Multi-million-pound funding to drive development of next-gen neural implant, neuromodulation and neurosensing therapeutics for clinical use LONDON, Jan. 31, 2025...
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
MemorialCare Long Beach Medical Center Becomes First in California to Adopt Stryker’s New Q Guidance System with Spine Guidance Software
Advanced surgical planning and navigation technology enhances precision and expands options for spine surgery, cutting down the length of surgery,...